Patent intelligence · US
US 10391097
Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
Patent details — US 10391097
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 27, 2019
- Expiration
- Aug 22, 2039
- Applicant
- VTV THERAPEUTICS LLC
- Claims
- 16
- CPC classes
- A61K, A61K31/519, A61P, A61P1/00
Quick answer
US 10391097 (Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors) is held by VTV THERAPEUTICS LLC. Status: granted. Granted Aug 27, 2019. Expires Aug 22, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- VTV THERAPEUTICS LLC
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/519, A61P, A61P1/00, A61P1/02, A61P1/04
More from VTV THERAPEUTICS LLC
Related pharmaceutical patents in our USPTO index.
-
US 12391658
Sulfoxide and sulfone glucokinase activators and methods of use thereof
granted -
US 12091407
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 11974989
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
granted -
US 11970457
Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine
granted -
US 11883383
Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
granted -
US 11833136
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
granted -
US 11649230
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 11524942
Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine
granted
Frequently asked questions
What is US patent 10391097?
US 10391097 (Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors) is held by VTV THERAPEUTICS LLC. Status: granted. Granted Aug 27, 2019. Expires Aug 22, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10391097?
VTV THERAPEUTICS LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 50 pharmaceutical patents for this assignee.
When does US 10391097 expire?
Our index shows an expiration date of Aug 22, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.